Aurobindo Pharma Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,378.15Overvalued by 19.69%vs CMP ₹1,716.00

P/E (26.1) × ROE (10.1%) × BV (₹652.00) × DY (0.23%)

₹956.80Overvalued by 44.24%vs CMP ₹1,716.00

MoS: -79.3% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹1,458.67	22%	Over (-15%)
Graham Number	Earnings	₹938.50	16%	Over (-45.3%)
Earnings Power	Earnings	₹296.31	11%	Over (-82.7%)
DCF	Cash Flow	₹709.58	13%	Over (-58.6%)
Net Asset Value	Assets	₹658.54	7%	Over (-61.6%)
EV/EBITDA	Enterprise	₹1,284.84	9%	Over (-25.1%)
Earnings Yield	Earnings	₹600.40	7%	Over (-65%)
ROCE Capital	Returns	₹1,337.40	9%	Over (-22.1%)
Revenue Multiple	Revenue	₹551.36	5%	Over (-67.9%)
Consensus (9 models)		₹956.80	100%	Overvalued

Key Drivers: Wide model spread (₹296–₹1,459) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 5.8%

*Investments are subject to market risks

Analysis summary

Data coverage: Price-data record updated 25 September 2026, 7:28 am +05:30. Annual results through Mar 2025; quarterly results through Dec 2025; cash flow through Mar 2026. Each section can have a different reporting period. The share price is not live.

Valuation in context

Operating performance

Revenue for Mar 2025 was ₹31,724.00 Cr, versus ₹29,002.00 Cr in Mar 2024 (9.4% year on year). Net profit for Mar 2025 was ₹3,484.00 Cr, versus ₹3,169.00 Cr in Mar 2024 (9.9% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.

Cash generation

For the same Mar 2025 period, operating cash flow was ₹3,925.00 Cr against net profit of ₹3,484.00 Cr. Cash flow covered 1.13 times reported profit. Cash generation supports the reported profit for this period; check whether this continues over several years.

Balance-sheet check

Reported borrowings were ₹8,073.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.

How to use the valuation and peer comparisons

The Intrinsic Value panel combines the available model estimates using the displayed weights. Earnings, cash-flow, dividend and asset-based methods can give very different answers. The displayed 12% cost of equity and 4% terminal growth assumptions apply where relevant; historical EPS growth is not a promise of future growth. Use the individual values and their spread to judge sensitivity.

The peer group follows the stored industry classification and may include different business models. Compare reporting periods, leverage and recurring earnings before interpreting a valuation gap. For banks and other financial businesses, capital adequacy and asset quality can be more informative than industrial-company cash-flow ratios.

Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.

Automatically generated interpretation of the stored financial data, not a separately researched analyst opinion. Missing data is not evidence of poor performance. New filings become available here after the existing data refresh process captures them.

Investment Snapshot

Aurobindo Pharma Ltd scores 74/100 (Strong)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health84/100 · Strong

ROCE 12.9% GoodROE 10.1% AverageD/E 0.24 Low debtInterest Coverage 15.8x StrongProfitable 5/5 available years Reported history

Smart Money60/100 · Moderate

FII holding up 2.17% (6mo) AccumulatingDII holding down 2.55% MF sellingPromoter holding at 51.9% Stable

Earnings Quality100/100 · Strong

CFO/NP ratio: 1.02x Cash-backed earningsOPM expanding (17% → 21%) ImprovingWorking capital: 49 days (improving) Efficient

Quarterly Momentum50/100 · Moderate

Revenue (4Q): +7% YoY GrowingProfit (4Q): 0% YoY Declining

Industry Rank55/100 · Moderate

P/E 26.1 vs industry 56.6 Lower P/EROCE 12.9% vs industry 26.2% Below peers3Y sales CAGR: 11% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores use stored reporting periods and are screening indicators, not investment recommendations. Missing health ratios are excluded. Broad industry groups and financial-sector accounting can limit comparability.

Share Price and Basic Stock Data

Last Updated: September 25, 2026, 7:28 am

Market Cap	98,735 Cr.
Current Price	1,716
Intrinsic Value	₹956.80
High / Low	1,740/1,066
Stock P/E	26.1
Book Value	652
Dividend Yield	0.23 %
ROCE	12.9 %
ROE	10.1 %
Face Value	1.00
PEG Ratio	4.47

Understand these figures: how to read the P/E ratio, ROE versus earnings per share, and calculate intrinsic value.

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Aurobindo Pharma Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Aurobindo Pharma Ltd	98,735 Cr.	1,716	1,740/1,066	26.1	652	0.23 %	12.9 %	10.1 %	1.00
Dr Reddys Laboratories Ltd	1,00,195 Cr.	1,200	1,415/1,080	31.1	454	0.67 %	13.0 %	11.2 %	1.00
Lupin Ltd	96,063 Cr.	2,101	2,530/1,900	16.1	491	0.86 %	29.9 %	28.7 %	2.00
Mankind Pharma Ltd	1,03,261 Cr.	2,500	2,642/1,910	45.7	397	0.04 %	13.7 %	13.8 %	1.00
Laurus Labs Ltd	1,09,478 Cr.	2,026	2,055/823	125	97.3	0.10 %	16.0 %	15.2 %	2.00
Industry Average	23,323.71 Cr	1,277.38		56.60	211.60	0.38%	26.16%	16.59%	6.06

All Competitor Stocks of Aurobindo Pharma Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	6,407	6,473	6,851	7,219	7,352	7,580	7,567	7,796	7,979	8,382	7,868	8,286	8,646
Expenses	5,453	5,477	5,702	5,846	5,753	5,920	5,949	6,230	6,401	6,622	6,265	6,608	6,873
Operating Profit	954	996	1,149	1,373	1,599	1,660	1,618	1,566	1,578	1,760	1,603	1,678	1,773
OPM %	15%	15%	17%	19%	22%	22%	21%	20%	20%	21%	20%	20%	21%
Other Income	93	135	47	188	163	14	221	136	159	135	107	122	123
Interest	45	56	57	68	76	89	111	113	118	115	98	95	93
Depreciation	321	346	327	418	423	354	404	382	419	444	406	429	465
Profit before tax	680	730	812	1,076	1,262	1,230	1,324	1,207	1,200	1,335	1,207	1,276	1,339
Tax %	28%	31%	30%	30%	26%	26%	31%	32%	30%	32%	32%	34%	32%
Net Profit	491	506	570	752	940	907	918	817	846	903	824	848	910
EPS in Rs	8.38	8.64	9.74	12.92	15.98	15.51	15.69	14.07	14.56	15.56	14.20	14.61	15.67

Last Updated: March 3, 2026, 12:04 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 11:30 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	8,089	12,103	13,772	14,910	16,463	19,564	23,099	24,775	23,455	24,855	29,002	31,724	33,182
Expenses	5,951	9,524	10,579	11,469	12,691	15,612	18,249	19,497	19,060	21,148	23,176	25,173	26,368
Operating Profit	2,137	2,579	3,193	3,441	3,772	3,952	4,849	5,278	4,396	3,707	5,826	6,551	6,814
OPM %	26%	21%	23%	23%	23%	20%	21%	21%	19%	15%	20%	21%	21%
Other Income	18	81	200	115	105	70	166	3,195	152	291	366	622	487
Interest	310	160	257	67	78	263	305	74	49	140	290	457	401
Depreciation	313	333	392	428	558	668	967	1,055	1,127	1,245	1,522	1,649	1,744
Profit before tax	1,533	2,168	2,744	3,061	3,241	3,091	3,743	7,344	3,373	2,612	4,380	5,066	5,156
Tax %	24%	28%	26%	25%	25%	24%	24%	27%	22%	26%	28%	31%
Net Profit	1,169	1,571	2,024	2,301	2,423	2,364	2,844	5,334	2,647	1,928	3,169	3,484	3,485
EPS in Rs	20.12	26.98	34.61	39.29	41.36	40.36	48.56	91.05	45.20	32.90	54.15	60.02	60.04
Dividend Payout %	7%	8%	7%	6%	6%	6%	6%	4%	20%	23%	8%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	34.39%	28.84%	13.69%	5.30%	-2.43%	20.30%	87.55%	-50.37%	-27.16%	64.37%	9.94%
Change in YoY Net Profit Growth (%)	0.00%	-5.55%	-15.15%	-8.38%	-7.74%	22.74%	67.25%	-137.93%	23.21%	91.53%	-54.43%

Aurobindo Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	10%
5 Years:	7%
3 Years:	11%
TTM:	8%

Compounded Profit Growth
10 Years:	8%
5 Years:	4%
3 Years:	8%
TTM:	-5%

Stock Price CAGR
10 Years:	4%
5 Years:	5%
3 Years:	24%
1 Year:	-32%

Return on Equity
10 Years:	15%
5 Years:	12%
3 Years:	10%
Last Year:	11%

Last Updated: September 5, 2025, 2:31 pm

Balance Sheet

Last Updated: May 26, 2026, 4:00 am

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	29	59	59	59	59	59	59	59	59	59	58	58
Reserves	5,127	7,229	9,313	11,622	13,832	16,766	21,871	24,517	26,781	29,784	32,595	37,833
Borrowings	4,451	5,041	3,364	4,770	6,967	5,826	5,339	2,851	5,286	6,648	8,263	8,073
Other Liabilities	3,303	3,568	3,464	4,492	5,414	6,113	6,147	6,211	7,379	8,227	8,566	12,538
Total Liabilities	12,910	15,896	16,200	20,942	26,271	28,765	33,416	33,638	39,505	44,717	49,482	58,502
Fixed Assets	3,706	4,180	4,834	6,521	8,475	9,396	9,374	10,532	11,024	14,493	14,794	19,611
CWIP	420	848	1,458	1,583	1,668	1,986	3,062	3,747	5,390	3,869	4,900	3,009
Investments	20	123	246	312	360	555	591	997	543	372	252	1,051
Other Assets	8,765	10,745	9,662	12,527	15,768	16,827	20,390	18,362	22,549	25,983	29,536	34,831
Total Assets	12,910	15,896	16,200	20,942	26,271	28,765	33,416	33,638	39,505	44,717	49,482	58,502

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	1,237	1,420	3,279	1,955	1,651	4,381	3,329	5,016	2,387	2,435	3,925	5,526
Cash from Investing Activity +	-1,017	-1,446	-1,787	-1,927	-2,904	-1,563	597	-3,211	-3,971	-4,242	-1,866	-2,630
Cash from Financing Activity +	93	365	-1,915	864	1,919	-1,947	-1,365	-2,969	1,814	800	120	-1,269
Net Cash Flow	313	340	-424	892	666	871	2,561	-1,164	230	-1,007	2,178	1,628
Free Cash Flow	491	-146	1,594	714	114	2,969	1,503	2,693	-323	-1,067	1,408	2,468
CFO/OP	67%	67%	118%	70%	61%	106%	87%	143%	84%	72%	86%	107%

Free Cash Flow

Free cash flow reported in the stored cash-flow statement (₹ Cr)
Period	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Free Cash Flow	491.00	-146.00	1,594.00	714.00	114.00	2,969.00	1,503.00	2,693.00	-323.00	-1,067.00	1,408.00	2,468.00

This table and the chart use the Free Cash Flow row from the same stored cash-flow statement. Free cash flow generally measures operating cash flow after capital expenditure; check the source definition and reporting basis. It is not operating profit minus borrowings.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	119	107	122	68	68	64	68	52	62	66	61	66
Inventory Days	240	239	240	246	317	304	289	333	272	275	284	295
Days Payable	137	136	146	122	128	107	97	103	97	125	129	117
Cash Conversion Cycle	222	210	217	191	257	260	260	282	237	216	216	244
Working Capital Days	56	50	44	51	50	25	35	52	84	55	66	49
ROCE %	27%	27%	27%	25%	23%	18%	19%	18%	13%	9%	14%	14%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	51.84%	51.84%	51.84%	51.80%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.88%
FIIs	22.45%	20.72%	18.01%	16.73%	16.59%	16.29%	15.33%	14.38%	14.21%	13.95%	15.24%	16.38%
DIIs	18.29%	20.60%	23.28%	24.77%	25.14%	25.21%	26.23%	26.93%	27.60%	27.66%	25.82%	25.05%
Government	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.03%	0.05%	0.05%
Public	7.43%	6.85%	6.87%	6.69%	6.45%	6.67%	6.61%	6.88%	6.37%	6.55%	7.08%	6.63%
No. of Shareholders	2,59,638	2,41,944	2,44,575	2,38,622	2,48,488	2,57,962	2,69,323	2,72,208	2,47,662	2,36,859	2,41,298	2,39,073

Shareholding Pattern Chart

No. of Shareholders

Aurobindo Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
HDFC Mid Cap Fund	13,344,745	1.73	1628.59	N/A	N/A	N/A
Quant ELSS Tax Saver Fund	6,710,355	6.78	818.93	5,174,277	2026-02-23 00:53:04	29.69%
Quant Mid Cap Fund	5,969,000	9.92	728.46	N/A	N/A	N/A
SBI Large & Midcap Fund	5,400,000	1.7	659.02	6,500,000	2026-03-23 01:28:44	-16.92%
Quant Multi Cap Fund	4,294,483	7.21	524.1	N/A	N/A	N/A
ICICI Prudential India Opportunities Fund	3,775,289	1.29	460.74	4,403,987	2026-03-24 00:22:07	-14.28%
ICICI Prudential Value Fund	3,230,588	0.65	394.26	N/A	N/A	N/A
Quant Flexi Cap Fund	3,030,611	5.82	369.86	N/A	N/A	N/A
HDFC Balanced Advantage Fund	2,722,312	0.31	332.23	N/A	N/A	N/A
HDFC Large and Mid Cap Fund	2,177,529	0.93	265.75	N/A	N/A	N/A

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	59.81	54.16	32.90	45.19	91.05
Diluted EPS (Rs.)	59.81	54.16	32.90	45.19	91.05
Cash EPS (Rs.)	88.92	80.35	54.34	64.94	109.99
Book Value[Excl.RevalReserv]/Share (Rs.)	562.21	509.49	458.30	419.42	374.28
Book Value[Incl.RevalReserv]/Share (Rs.)	562.21	509.49	458.30	419.42	374.28
Revenue From Operations / Share (Rs.)	546.21	495.00	424.23	400.33	422.85
PBDIT / Share (Rs.)	124.05	109.24	68.43	80.34	97.53
PBIT / Share (Rs.)	95.65	83.27	47.19	61.11	79.52
PBT / Share (Rs.)	87.78	75.05	44.79	58.10	126.28
Net Profit / Share (Rs.)	60.52	54.38	33.10	45.71	91.98
NP After MI And SOA / Share (Rs.)	60.02	54.16	32.90	45.20	91.05
PBDIT Margin (%)	22.71	22.06	16.13	20.06	23.06
PBIT Margin (%)	17.51	16.82	11.12	15.26	18.80
PBT Margin (%)	16.06	15.16	10.55	14.51	29.86
Net Profit Margin (%)	11.08	10.98	7.80	11.41	21.75
NP After MI And SOA Margin (%)	10.98	10.94	7.75	11.29	21.53
Return on Networth / Equity (%)	10.67	10.63	7.18	10.77	24.32
Return on Capital Employeed (%)	15.82	14.84	9.73	13.89	20.09
Return On Assets (%)	7.00	7.03	4.83	7.80	15.75
Long Term Debt / Equity (X)	0.04	0.07	0.02	0.01	0.01
Total Debt / Equity (X)	0.24	0.21	0.18	0.09	0.22
Asset Turnover Ratio (%)	0.66	0.68	0.67	0.69	0.78
Current Ratio (X)	1.85	1.98	1.87	2.22	1.86
Quick Ratio (X)	1.13	1.18	1.13	1.30	1.01
Inventory Turnover Ratio (X)	3.12	1.18	1.20	0.88	0.99
Dividend Payout Ratio (NP) (%)	0.00	0.00	22.79	9.95	4.39
Dividend Payout Ratio (CP) (%)	0.00	0.00	13.85	6.98	3.66
Earning Retention Ratio (%)	0.00	0.00	77.21	90.05	95.61
Cash Earning Retention Ratio (%)	0.00	0.00	86.15	93.02	96.34
Interest Coverage Ratio (X)	15.76	22.09	28.54	96.77	76.71
Interest Coverage Ratio (Post Tax) (X)	8.69	12.66	14.80	58.70	35.56
Enterprise Value (Cr.)	67055.18	63875.80	29138.94	37374.61	51145.96
EV / Net Operating Revenue (X)	2.11	2.20	1.17	1.59	2.06
EV / EBITDA (X)	9.31	9.98	7.27	7.94	8.95
MarketCap / Net Operating Revenue (X)	2.12	2.20	1.22	1.67	2.08
Retention Ratios (%)	0.00	0.00	77.20	90.04	95.60
Price / BV (X)	2.06	2.14	1.13	1.59	2.36
Price / Net Operating Revenue (X)	2.12	2.20	1.22	1.67	2.08
EarningsYield	0.05	0.04	0.06	0.06	0.10

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Frequently asked questions

What is the intrinsic value of Aurobindo Pharma Ltd and is it undervalued?

Aurobindo Pharma Ltd: the stored intrinsic value estimate is ₹956.80, compared with a stored share price of ₹1,716.00. The model value is 44.2% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation. The estimate uses the available valuation models and weights shown in the Intrinsic Value panel, including earnings, cash-flow and asset-based approaches where data permits. It is not a P/E-only calculation.

What share price and 52-week range are shown for Aurobindo Pharma Ltd?

The stored share price is ₹1,716.00. Price-data record updated: 25 September 2026, 7:28 am +05:30. This is not a live quote. The stored 52-week high / low is 1,740/1,066; this is a rolling range, not a financial-year range.

How have Aurobindo Pharma Ltd's revenue and profit changed?

Does Aurobindo Pharma Ltd's profit convert into cash?

What should I check in Aurobindo Pharma Ltd's balance sheet?

Reported borrowings were ₹8,073.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.

How should I compare Aurobindo Pharma Ltd's P/E with other stocks?

The stored P/E is 26.10. Compare companies with similar business models, growth, leverage and accounting periods. The industry group on this page is broad, and its average can be affected by outliers. A lower P/E alone does not establish undervaluation.

What could change Aurobindo Pharma Ltd's intrinsic value estimate?

Changes in sustainable earnings, cash generation, capital needs, debt and share count can change the estimate. The displayed model uses a 12% cost of equity and 4% terminal growth assumption where applicable. Higher discount rates or weaker growth generally reduce discounted values. Compare the individual model values and weights, and verify fresh filings before relying on the result.